Checkmate-227 study at ESMO 2019

posted in: Blog | 0

November 2019 By Tom Newsom-Davis, BTOG Vice-Chair 1st Line Combination Immunotherapy for NSCLC: Checkmate-227 Further results from the Checkmate-227 trial were presented at ESMO 2019. Checkmate-227 is a study with multiple treatment arms, which has released results at various stages … Read More

FLAURA study at ESMO 2019

posted in: Blog | 0

November 2019 By Tom Newsom-Davis, BTOG Vice-Chair 1st Line Osimertinib Overall Survival Results: FLAURA The overall survival (OS) date from the FLAURA study was presented at the Presidential Session of ESMO 2019, following publication of the Progression Free Survival (PFS) … Read More

Medical Oncology at WCLC 2019

posted in: Blog | 0

October 2019 By Tom Newsom-Davis, BTOG Vice-Chair Treatment of RET-Fusion NSCLC: LIBRETTO-001 RET fusions are found in a number of different cancer and account for approximately 2% of NSCLC. Although rare, they are predominantly found in younger patients, non-smokers or … Read More

Mesothelioma Essential Update 2019

posted in: Blog | 0

March 2019 By Liz Darlison, Head of Services and Clinical Nurse Specialist for Mesothelioma UK and Professor James Spicer, BTOG Steering Committee Member. An Essential Update on mesothelioma, organised by the British Thoracic Oncology Group and Mesothelioma UK, was held … Read More

WCLC Highlights

posted in: Blog | 0

October 2018 By James Spicer, Professor of Experimental Cancer Medicine and Consultant in Medical Oncology ALTA1: brigatinib vs crizotinib in ALK-rearranged non-small cell lung cancer The initial results of this comparison of brigatinib with the first generation drug crizotinib were presented … Read More

1 2